FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Orphan Status for Multiple Myeloma Therapy

FDA grants Nexcella an orphan drug designation for its CAR-T cell therapy NXC-201 for treating multiple myeloma.

latest-news-card-1
Human Drugs

Objectionable Conditions in Clinical Investigation

FDA warns Angela Stupi in Cranberry Twp., PA, about violations in her conduct of two trials with investigational drugs.

latest-news-card-1
Federal Register

Oncologic Panel to Review Amgens Lumakras

Federal Register notice: FDA announces a 10/5 Oncologic Drugs Advisory Committee meeting to discuss an Amgen supplemental NDA for Lumakras (sotorasib)...

Medical Devices

OTC Devices Dont Need Patient Self-Diagnosis: CHPA

The Consumer Healthcare Product Association tells CDRH patient self-diagnosis need not be a requirement for the at-home use of over-the-counter medica...

latest-news-card-1
Human Drugs

FDA Warns Walmart, Amazon on Molluscum Drugs

FDA warns Walmart and Amazon they are illegally distributing unapproved new drugs to treat molluscum contagiosum.

latest-news-card-1
Medical Devices

Ambu Illegally Selling Airway Device: FDA

FDA warns Noblesville, IN-based Ambu, Inc., that it is illegally distributing an unapproved medical device.

latest-news-card-1
Human Drugs

Clinical Hold Lifted on Sickle Cell Drug

FDA lifts a clinical hold against a Fulcrum Therapeutics IND for FTX-6058 for the potential treatment of sickle-cell disease.

latest-news-card-1
Federal Register

More ANDA Bioequivalence Draft Guides Posted

Federal Register notice: FDA makes available additional draft and revised draft product-specific guidances for generic drug developers.

latest-news-card-1
Human Drugs

Require Generic Ozobax Safety Data: Metacel

Metacel says FDA must require sponsors of generic Ozobax to perform and submit the same flavoring safety data that Metacel was required to submit.

latest-news-card-1
Human Drugs

FDA Reorg Could Hurt Supplements: Duncan

South Carolina GOP Rep. Jeff Duncan says FDA should retain the Office of Dietary Supplement Programs as a freestanding entity rather than merging it i...